All In Biotech

Drug Trial Radar · NCT01999686

PCOS Treatment Using DLBS3233, Metformin, and Combination of Both

Polycystic Ovary Syndrome Treatment Using DLBS3233, Metformin, and Combination of Both, and Its Relation to Fertility

Last checked: Nov 19, 2026Latest source record: May 28, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 186 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

186

Actual

Start

Oct 2014

Primary completion

Feb 2019

Study completion May 2019

Sponsor

Lead sponsor
Dexa Medica GroupIndustry
Sponsor type
Industry
First posted
Dec 3, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 3-arm, randomized, double-blind, double-dummy, and controlled clinical study over 6 months of treatment to evaluate the metabolic and clinical efficacy as well as the safety of DLBS3233 alone, metformin and combination of both, in improving metabolic and reproductive parameters.

Conditions

  • Polycystic Ovary Syndrome (PCOS)
  • Insulin Resistance

Interventions

  • DLBS3233Drug

  • Metformin XRDrug

  • Placebo metforminDrug

    Placebo metformin has the same ingredients with Metformin XR caplet, except that it does not contain the active substance (metformin).

  • Placebo DLBS3233Drug

    Placebo DLBS3233 has the same ingredients with DLBS3233 capsule, except that it does not contain the active substance (DLBS3233).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HOMA-IR reductionTime frame: 6 months

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Lambung Mangkurat, Ulin Banjarmasin Hospital

    Banjarmasin, Indonesia

  • Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Udayana, Sanglah Hospital

    Denpasar, Indonesia

  • Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Hasanuddin, Dr. Wahidin Sudirohusodo Hospital

    Makasar, Indonesia

  • Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Brawijaya, Dr. Saiful Anwar Hospital

    Malang, Indonesia

  • Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Sam Ratulangi, Prof. Dr. Kandou Hospital

    Manado, Indonesia

  • Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, Diponegoro University, Dr. Kariadi Hospital

    Semarang, Indonesia

  • Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Airlangga, Dr. Soetomo Hospital.

    Surabaya, Indonesia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.